CapeBio
CapeBio develops and supplies molecular biology reagents, diagnostic assays, enzymes, and related medical devices for clinical and research use. The company uses a proprietary bio-discovery artificial intelligence platform to mine African microbial diversity for novel biomolecules and commercializes enzyme technologies and nucleic-acid assays such as PCR mastermixes, RT-qPCR and LAMP tests. CapeBio produces in vitro diagnostics and lab reagents, pursues regulatory approvals (including SAHPRA for SARS-CoV-2 kits), and supports healthcare providers, diagnostic companies, and research laboratories. The business operates as a product-focused biotechnology company with complementary R&D and software-driven discovery capabilities targeting healthcare and diagnostic markets in Africa and beyond.
CapeBio
CapeBio develops and supplies molecular biology reagents, diagnostic assays, enzymes, and related medical devices for clinical and research use. The company uses a proprietary bio-discovery artificial intelligence platform to mine African microbial diversity for novel biomolecules and commercializes enzyme technologies and nucleic-acid assays such as PCR mastermixes, RT-qPCR and LAMP tests. CapeBio produces in vitro diagnostics and lab reagents, pursues regulatory approvals (including SAHPRA for SARS-CoV-2 kits), and supports healthcare providers, diagnostic companies, and research laboratories. The business operates as a product-focused biotechnology company with complementary R&D and software-driven discovery capabilities targeting healthcare and diagnostic markets in Africa and beyond.